Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

ClinicalTrials.gov ID: NCT02014376

Public ClinicalTrials.gov record NCT02014376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).

Study identification

NCT ID: NCT02014376
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Scioderm, Inc.; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

Epidermolysis Bullosa

Interventions

Drug

Eligibility (public fields only)

Age range: 6 Months and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 6, 2014 (Actual)
Primary completion: Jun 24, 2014 (Actual)
Completion: Jun 24, 2014 (Actual)
Last update posted: Jan 13, 2020

2014

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Not listed	Palo Alto	California	94304	—
Not listed	Chicago	Illinois	60611	—
Not listed	St Louis	Missouri	63110	—
Not listed	Hackensack	New Jersey	07601	—
Not listed	Chapel Hill	North Carolina	27516	—
Not listed	San Antonio	Texas	78218	—
Not listed	Seattle	Washington	98105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02014376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 13, 2020 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02014376 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →